CUSTOMERCARE DEL GRUPPO UESE

INVIARE RICHIESTE | PRATICHE | TRACCIARE STATO DI AVANZAMENTO RICHIESTE

In Vitro Diagnostics EUAs

In vitro diagnostic (IVD) devices are tests performed on samples taken from the human body, such as swabs of mucus from inside the nose or back of the throat, or blood taken from a vein or fingerstick. IVDs can detect diseases or other conditions and can be used to monitor a person's overall health to help cure, treat, or prevent diseases. There are several types of SARS-CoV-2 and COVID-19 related IVDs:

  • Diagnostic Tests - Tests that detect parts of the SARS-CoV-2 virus and can be used to diagnose infection with the SARS-CoV-2 virus. These include molecular tests and antigen tests.
  • Serology/Antibody Tests - Tests that detect antibodies (e.g., IgM, IgG) to the SARS-CoV-2 virus. Serology/antibody tests cannot be used to diagnose a current infection.
  • Tests for Management of COVID-19 Patients - Beyond tests that diagnose or detect SARS-CoV-2 virus or antibodies, there are also tests that are authorized for use in the management of patients with COVID-19, such as to detect biomarkers related to inflammation. Once patients are diagnosed with COVID-19 disease, these additional tests can be used to inform patient management decisions.

Any test developer requesting an EUA that intends to leverage data from another EUA-authorized device must obtain a right of reference to leverage the performance data for that EUA-authorized device. The Centers for Disease Control and Prevention (CDC) has granted a right of reference to the performance data contained in CDC's EUA request (FDA submission number EUA200001) to any entity seeking an FDA EUA for a COVID-19 diagnostic device.

Templates for these EUA submissions are available to help facilitate the preparation, submission, and authorization of an EUA:

These templates are part of the Policy for Coronavirus Disease-2019 Tests During the Public Health Emergency (Revised) - Immediately in Effect Guidance for Clinical Laboratories, Commercial Manufacturers, and Food and Drug Administration Staff, which also includes additional policies specific to this public Health emergency. The templates reflect FDA's current thinking on the data and information that developers should submit to facilitate the EUA process. The templates provide information and recommendations, and we plan to update them as appropriate as we learn more about the COVID-19 disease and gain experience with the EUA process for the various types of COVID-19 tests.

Developers who intend to use alternative approaches should consider seeking the FDA's feedback or recommendations to help them through the EUA process. The FDA encourages developers to discuss any alternative technological approaches to validating their test with the FDA through CDRH-EUA-Templates@fda.hhs.gov.

Members of the public can submit questions about the templates to CDRH-EUA-Templates@fda.hhs.gov, or they can submit comments regarding the templates to the public docket established for the guidance Policy for Coronavirus Disease-2019 Tests During the Public Health Emergency (Revised) - Immediately in Effect Guidance for Clinical Laboratories, Commercial Manufacturers, and Food and Drug Administration Staff.

Test developers interested in pursuing an EUA may submit a pre-EUA to begin discussions with the FDA or may submit an EUA request to CDRH-EUA-Templates@fda.hhs.gov.

Additional information can be found on the FAQs on Testing for SARS-CoV-2 webpage.

Tables of IVD EUAs:


Individual EUAs for Molecular Diagnostic Tests for SARS-CoV-2

This table includes information about authorized SARS-CoV-2 molecular diagnostic tests. These EUAs have been issued for each individual test with certain conditions of authorization required of the manufacturer and authorized laboratories. Test attributes are listed in the “Attributes” column. For example, tests authorized for the screening of asymptomatic individuals without known exposure are listed with “screening” in the attribute column; pooling, multi-analyte, saliva, home collection, and home testing are similarly listed. Tests available without a prescription include the attribute “DTC” (for direct-to-consumer home collection tests) or “OTC” (for over-the-counter at-home tests).

Dettagli articolo

Codice articolo:
169
Categoria:
Visualizzazioni:
67
Valutazione (Voti):
(0)

Articoli correlati

UESE ITALIA S.p.A.
Sede e Direzione generale: 30172 Corso del Popolo 58/B – Venezia Tel. 0418723000

Società assoggettata a sistemi di gestione:
ISO 9001:2015 EA37 –  ISO 14001  –  ISO 45001  –  ISO 27000 Audit & Service

Phone:+39 418723000 | Fax:+39 8723001  |  Email: info@uese.it
Legalmail: unitedsafety@pec.it    SDI: 3ZJY534

Socia di ALIS | FDAEXPRESS | UniPoste | FSC Italia
Copyright 2014 -2021 © UESE ITALIA S.p.A. All rights reserved. Iscrizione O.NA.P.S. Organismo Nazionale Professionisti della Sicurezza 2838 Iscrizione ASSODPO Associazione Data Protection Officer 755 101178
P. Iva IT04398760274 | Cap. Sociale 250.000 €